Protalix Earnings Call: EU Win, Cash Boost, Trade-Offs

Protalix Biotherapeutics ((PLX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Protalix Biotherapeutics’ latest earnings call mixed upbeat clinical and commercial progress with a more cautious financial picture. Management highlighted EU approval of a differentiated 4‑week Elfabrio regimen and a sizable $25 million milestone that strengthens liquidity. Yet higher R&D spending, a swing to net loss, and execution risks around reimbursement and U.S. labeling kept the tone balanced rather than euphoric.

European Green Light for Elfabrio’s 4-Week Regimen

The European Commission cleared a 2 mg/kg every‑4‑week Elfabrio dosing option for adults stable on enzyme replacement therapy. This less‑frequent regimen differentiates Elfabrio from rivals and is expected to strengthen its competitive position across EU markets over time.

Milestone Payment Bolsters Cash Reserves

The EU decision immediately triggered a $25 million regulatory milestone from partner Chiesi, materially improving Protalix’s near‑term liquidity profile. Management now projects cash and equivalents of roughly $50 million by early April 2026, up from $30.3 million at year‑end 2025.

Revenue Outlook Signals Strong 2026 Upswing

For 2026, Protalix guided to total revenues between $78 million and $83 million, including the $25 million milestone from Chiesi. Chiesi‑related revenues are expected to reach $33 million to $35 million, implying more than 50% growth year over year, while Elelyso should contribute about $20 million to $23 million.

Chiesi’s Execution Drives Elfabrio Patient Uptake

Chiesi reported steady growth in Elfabrio patients in the U.S. and key ex‑U.S. markets, capturing both treatment‑naive and switch patients. Management framed this as evidence of strong partner execution in a Fabry disease market projected to reach roughly $3.4 billion by 2030.

PRX-115 Study Progresses in Uncontrolled Gout

The Phase II RELEASE trial for PRX‑115 is now actively enrolling, with first patients randomized and topline data targeted for the second half of 2027. Protalix is positioning PRX‑115 as a potential best‑in‑class therapy for uncontrolled gout, including the possibility of differentiated dosing schedules.

Broader Pipeline and Partnership Optionality

Beyond Elfabrio and PRX‑115, the company is building a rare renal pipeline that includes PRX‑119, a long‑acting DNase candidate. Protalix is also collaborating with Secarna on RNA‑based programs, signaling strategic intent to diversify future revenue drivers beyond current products.

Cost Structure Shows Early Signs of Improvement

Selling, general and administrative expenses dipped slightly to $11.7 million in 2025, helped by lower share‑based compensation. Interest expense also fell after the full repayment of secured convertible notes in 2024, though some of this benefit was offset by foreign‑exchange‑related financial charges.

From Profit to Loss as R&D Weighs on 2025

Protalix posted a 2025 net loss of $6.6 million, a notable reversal from the $2.9 million net income generated in 2024. Management attributed the $9.5 million swing mainly to heavier R&D investment as the clinical pipeline, led by PRX‑115, moved forward.

R&D Surge Fuels Pipeline but Lifts Cash Burn

R&D expenses jumped 51% year over year to $19.6 million in 2025, driven primarily by spending on the PRX‑115 RELEASE study. The company signaled that R&D outlays are likely to keep rising as programs advance, increasing near‑term cash burn despite incoming milestone payments.

Margin Pressure from Softer Sales Mix and Higher COGS

Full‑year 2025 revenues from selling goods came in at $51.8 million, a modest decline from 2024 levels. Cost of goods sold climbed to $27.0 million on higher sales to Pfizer and Fiocruz and lower sales to Chiesi, compressing gross margins and underscoring the importance of shifting toward higher‑margin revenue streams.

Year-End Cash Was Modest Before Milestone Boost

As of December 31, 2025, Protalix held $30.3 million in cash, cash equivalents and short‑term deposits, a relatively modest cushion for an R&D‑intensive business. The subsequent $25 million milestone significantly alleviates near‑term funding pressure but does not fully offset rising development spending.

EU Rollout Faces Gradual, Country-Specific Reimbursement

While the EU‑wide 4‑week dosing approval is secured, management cautioned that adoption will depend on country‑by‑country reimbursement decisions. They expect a gradual ramp, with more tangible volume and revenue contributions from the new regimen in the second half of 2026 and more meaningfully in 2027.

U.S. Dosing Label Remains an Unresolved Catalyst

In the U.S., Elfabrio currently remains on the 1 mg/kg every‑2‑weeks regimen, and management described it as premature to predict if or when a less‑frequent dosing schedule might be approved. This regulatory uncertainty leaves a potential upside catalyst on the table, but with no clear timeline for investors.

Guidance Highlights Growth, Liquidity and Mix Shift

Management’s guidance underscores a step‑change in 2026 revenue, with $78 million to $83 million expected, backed by the $25 million milestone and strong Chiesi revenue growth. They also forecast a cash balance near $50 million by early April 2026 and reiterated a strategic shift in revenue mix toward higher‑margin Chiesi‑related business as R&D investment in PRX‑115 and renal assets continues.

Protalix emerges from this earnings call as a company balancing near‑term financial strain against meaningful long‑term opportunity. EU dosing differentiation, stronger cash reserves and partner‑driven commercial momentum provide clear positives, while elevated R&D and reimbursement timing risks warrant caution. For investors, the story now hinges on execution in 2026 and clinical progress toward the 2027 PRX‑115 readout.